Barchart Demo Center



Stock Screeners




Fund Screeners

Foreign Exchange



Financial Calculators

Embedded Widgets



JSON Feeds

Symbol Overview

United States|Canada

Pfizer Inc

Add to Portfolio
-0.56 (-1.49%)
as of 14:04 EST

Last 37.10
Change -0.56 (-1.49%)
Open 37.57
Prev. Close 37.66
Today's Range
52wk Range
Volume 9,614,397
Avg Volume 20,695,891
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
PFE -1.49% -0.99% -14.91%
DJIA -0.67% +2.24% +13.17%
S&P 500 -0.62% +3.32% +17.09%

Key Statistics

Annual EPS 2.86
Dividend Yield 3.94%
P/E Ratio 12.02
Market Capitalization, $K 202,272,172
Weighted Alpha -14.70
Standard Deviation -1.44
Profit Margin 12.78%
Beta 0.67

Growth Rates

YTD -15.14%
1-Year -12.70%
3-Year +18.84%
5-Year +20.90%
10-Year +107.26%


Sell Hold Buy

Recent Headlines

Biotech Companies Focused on Cancer Research are Being

PR Newswire via COMTEX - 08:30AM EST
The global biotech market will surpass $775 billion USD by 2024; according to a new research report by Global Market Insights, Inc. The industry is one of the most exciting sectors to follow, acting as a strong engine of innovatio(full story)
KRTX: 101.12 (-22.87), BMY: 55.97 (-0.51), PFE: 37.10 (-0.56), ONCY: 0.95 (+0.06), SGEN: 121.35 (+3.47)

Asian shares retreat on poor Japan trade data, China

AP - Tue Nov 19, 10:34PM EST
BEIJING (AP) — Shares retreated in Asia on Wednesday after Japan reported its worst monthly decline in exports in three years, putting pressure on the economy as growth slows following a sales tax hike.(full story)
JWN: 33.80 (-1.70), HD: 220.93 (-4.93), PFE: 37.10 (-0.56), M: 15.00 (-0.04), AMGN: 224.26 (-0.24)

Akcea and Ionis Announce Closing of Licensing

GlobeNewswire via COMTEX - Tue Nov 19, 04:05PM EST
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (full story)
AKCA: 20.53 (+1.45), IONS: 59.70 (+1.61), PFE: 37.10 (-0.56)

FDA Approves Pfizer's Biosimilar, ABRILADA(TM)

BusinessWire via COMTEX - Mon Nov 18, 06:45AM EST
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA(TM)(adalimumab-afzb), as a biosimilar to Humira(R) (adalimumab),(1) for the treatment of certain patients wi(full story)
PFE: 37.10 (-0.56)

Bristol-Myers Squibb and Pfizer Announce Randomized,

BusinessWire via COMTEX - Fri Nov 15, 09:00AM EST
The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to (full story)
BMY: 55.97 (-0.51), PFE: 37.10 (-0.56)